Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.

Abstract: An extensible base process control and manufacturing information application development and execution software suite is disclosed that facilitates streamlined third party (e.g., OEM) development of derivative applications for particular vertical markets. The suite includes an object design toolkit that provides object template derivation tools for accessing and editing a set of base object templates. The objects derivable from the base templates include at least application objects deployed upon lower level hosting component objects of a supervisory process control and manufacturing information application. The toolkit also includes development tools for creating new base object templates that are added as extensions of the set of base object templates. In addition to the toolkit, the suite includes a set of marketing package customization tools facilitating seamlessly integrating changes by developers to the extensible base development and execution software suite.